Polycystic ovary syndrome resembling histopathological alterations in ovaries from prenatal androgenized female rats
© Wang et al.; licensee BioMed Central Ltd. 2012
Received: 7 April 2012
Accepted: 18 May 2012
Published: 18 May 2012
The polycystic ovary syndrome ( PCOS) affects approximately 6-10% of women of reproductive age and is characterized by chronic anovulation and hyperandrogenism. However, a comprehensive understanding of the mechanisms that dictate androgen overproduction is lacking, which may account for inconsistencies between measures of androgen excess and clinical presentation in individual cases.
A rat model of PCOS was established by injecting dehydroepiandrosterone sulfoconjugate (DHEAS) into pregnant females. Rats were administered with DHEAS (60 mg/kg/d) subcutaneously (s.c.) for all 20 days of pregnancy (Group A), or for the first 10 days (Group B), or from day 11 to day 20 (Group C). Controls were administered with injection oil (0.2 ml/day) s.c. throughout pregnancy (Group D). The litter rate, abortion rate, and offspring survival rate in each group were recorded. Serum androgen and estrogen were measured and the morphological features of the ovaries were examined by light and electron microscopy in the offspring of each group.
We found that rats injected with DHEAS throughout pregnancy (group A) lost fertility. Rats injected with DHEAS during early pregnancy (group B) exhibited more serious aberrations in fertility than both Group C, in which rats were injected with DHEAS during late pregnancy (P < 0.05), and Group D (controls). There was a statistical difference of ovarian weight among female offspring in Group B, C and D (P < 0.01). By light and electron microscopy, a significant morphological difference among the female offspring in the three groups was observed.
Our results indicate that androgen excess during pregnancy can decrease rat fertility. Excess androgen at the early stage of pregnancy causes high reproductive toxicity, leading to abnormality of ovarian morphology and functions in female offspring.
KeywordsPrenatal androgenization Polycystic ovary syndrome (PCOS) Ovarian Rat model
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in premenopausal women . In different ethic populations, the prevalence of PCOS is about 5-10% [2, 3]. In clinic, PCOS patients are usually diagnosed by a distinguishing polycystic appearance of the ovary and a wide range of biochemical markers including elevated serum androgens, insulin, luteinizing hormone (LH), and decreased insulin sensitivity . Both healthy women and women with abnormal cycles and hyperandroenism could develop PCOS, however, overweight or obese girls are much more predisposed to PCOS [4, 5].
Currently, the etiology of PCOS remains largely unknown. It is believed that both genetic factors and gestational environment contribute to its origin and development, and prenatal androgen exposure is considered one of the important factors in the early origins of PCOS [1, 6, 7]. It has been found that adrenal androgen excess presents in approximately 25-60% of women with PCOS, in which dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfoconjugate (DHEAS), and androstenedione are the most common androgens that are elevated [8, 9]. Epidemiological studies reported that girls at high risk for PCOS may have early androgen excess [10, 11]. Experiments with nonhuman primate model for PCOS demonstrated that prenatally androgenized female monkeys had enhanced basal and adrenocorticotropic hormone (ACTH)-stimulated adrenal androgen levels [8, 12–15]. In sheep, exposure of the pregnant ewe to large doses of testosterone causes increased LH secretion and abnormal ovarian cycles in female offspring [16–18]. Recently, studies proved that in uetro androgen exposure in adult female rats could also develop the PCOS related metabolic syndrome [19, 20]. Therefore, a strong association of PCOS development and prenatal androgen excess were well supported by literature.
The mechanisms for PCOS development caused by the prenatal androgenization are still under investigation. Human studies suggest continuing actions of hyperandrogenemia are important for sustaining the abnormal hypothalamic sensitivity to feedback inhibition by ovarian steroids . In cultured human theca cells from PCOS patients, 20 times more androstenedione was produced than normal cells [22, 23]. In rat models, prenatal androgenization leads to higher progesterone receptor mRNA expression and more LH secretion, prolonged anogenital distance and fewer nipple numbers, irregular or prolonged estrous cycles . Therefore, a global change in the reproductive system and ovarian functions in PCOS patients is suggested. As animal models are useful in understanding the pathogenesis of PCOS, it is important to examine the histopathological alterations in ovaries from prenatal androgenized animal models .
In current study, we established a rat model of PCOS by injecting androgen into pregnant females. The weight, morphology, and functions of the ovaries of female offspring in different treated groups were compared, and the detailed histopathological alterations in ovaries of prenatal androgenized female rats were examined. The major goal of this study is to determine the impact of prenatal androgenization on ovary development in female offspring, which is lacked in most reported literatures, and to provide new insights into the mechanisms of prenatal androgenization and PCOS development.
Animals and drugs
The study protocol was approved by the institutional Animal Care and Use Committee of Guangzhou Medical University. Rats were purchased from and housed in the Animal Center of Guangzhou Medical University. DHEAS and injection oil were purchased from Hubei Fangtong Pharmaceutical Co., Ltd. The rats were maintained on a controlled light cycle of 14:10 h (light/dark) at 25°C with water and food ad libitum. All animal procedures were reviewed and approved by the Guangzhou Medical University before implementation.
Administration of DHEAS
Rats were administered with DHEAS between 8:30 and 10:30 a.m. DHEAS (60 mg/kg/d) was dissolved in 0.2 ml injection oil and injected subcutaneously (s.c.) in the inner thighs of rats. The first day of pregnancy was defined by first sight of a vaginal plug. Thirty-two female SD rats (16-week-old, weighing 180–200 g) were randomly subdivided into 4 groups (Group A-D) for different treatments. Group A: rats were injected with DHEAS (60 mg/kg/d) during the whole pregnancy (day 1 to day 20). Group B: rats were injected with DHEAS (60 mg/kg/d) during the first half pregnancy (day 1 to day 10). Group C: rats were injected with DHEAS (60 mg/kg/d) during the second half pregnancy (day 11 to day 20). Group D (control): rats were injected with oil only (day 1 to day 20). The litter rate, abortion rate, and offspring survival rate were recorded. If abortion occurred, the rat was impregnated again after 1–2 weeks. The female offspring of each group were Group A’, B’, C’, and D’ accordingly, and their serum androgen and estrogen were measured and the morphological features of the ovaries were examined by light and electron microscopy. Experiments were repeated for at least 3 times, average results or representative figures were analyzed.
Determination of estrus cycle, pregnancy, and rate abortion
The estrus cycle was determined by vaginal exfoliative cytology and the ovulation was observed. The estrus cycle of rats is approximately 4–5 days, including proestrus, estrus, metestrus, and anestrus. The pregnancy period of rats is 21 days on average from first sight of the vaginal plus, and ranges from 19–23 days. To measure vaginal exfoliation, a cotton swab soaked in saline was inserted into the vagina, rotated, and the adherent mucous tissue smeared on slides for hematoxylin and eosin (HE) staining. The morphologic features of vaginal exfoliative cells were examined by light microscopy.
Early abortion, in which prenatal rats were not formed, was judged by weighing the dames, and by examining maternal bodies to see if abdomens were enlarged and if breasts were appropriately developed. No increase in body weight or reduced body weight, absence of abdominal enlargement, and lack of breast development were taken as signs of early abortion. Late abortion was measured by dead bodies in the cage. If the external genitalia of the maternal body or cushions were stained with blood, the offspring may have been eaten, which was also considered to be abortion. Offspring survival rates were obtained by dividing the number of adolescent rats by the number at birth in each group.
Measurement of serum sex hormones
The serum levels of sex hormone were determined by microparticle chemiluminescent immunoassay kits (Beckman Corporation of America) according to the manufacturer’s instructions. Intraday and interday coefficients of variation were below 10%. Three independent experiments were performed and the results were compared by independent sample t-test using SPSS 13.0 (SPSS Inc. USA). A two-sided P value of 0.05 was considered statistically significant.
Tissue sample collection and histochemistry
The offspring were sacrificed on the seventh day of the 10th week (equivalent to adolescence), and serum samples and ovaries were collected. Blood samples were collected by cardiac puncture, centrifuged at 2000 rpm, and plasma was collected and stored at −20°C for hormone analysis. After taking blood samples, both ovaries were quickly removed, cleared up and weighed. The visible morphologic changes of both ovaries including color and texture were recorded. After that, one ovary was quickly rinsed in phosphate buffered saline (PBS), fixed in 2.5% glutaraldehyde solution, and stored at 4°C for further processing and transmission electron microscopy, while the other ovary was fixed in 10% formalin solution and stored at 4°C for HE staining and light microscopic examination. Partly wax-enveloped ovarian tissues were stained with HE and the growth of follicles observed by microscopy and compared between offspring groups. The contralateral ovaries were prepared for transmission electron microscopy, and changes in their cellular and subcellular structures were analyzed and compared.
Litter rate, abortion rate, and offspring survival rate
During the first round of androgen treatment, pregnant rats in Groups A, B, and C had abortion rates of 100%, while the rate is 0% in Group D (controls). After abortion, the rats were kept in the same cage. No pregnancy occurred in Group A after 10 estrus cycles. Exfoliative cytoscopy of vagina showed that typical periodic changes in Group A rats were absent, while Groups B and C were able to become pregnant and carry litters to term. The offspring survival rate was 65% in Group B, 70.97% in Group C, and 71.43% in Group D. There was a statistical difference in survival rate between Group B and C (P < 0.05), and between Group B and D (P < 0.05) by independent sample t-test. No statistical difference in survival rate was found between Group C and D (P > 0.05).
Anatomic changes in offspring ovaries
The ovaries of Group B’ and C’ were slightly larger than those of Group D’. Some of ovaries of Group B’ and C’ were slightly red on the surface and no obvious vesicae were observed. The others were pale on the surface, and many vesicae were observed, especially in Group C’. The ovaries of Group D’ were uniformly red in color. The ovarian weight was 0.029 ± 0.007 g in Group B’, 0.030 ± 0.006 g in Group C’, and 0.026 ± 0.007 g in Group D’. There was a statistical difference between Group D’ and the combined Group B’ and C’ (P < 0.05), but no significant difference between Groups B’ and C’(P > 0.05).
Observation of ovaries in neonatal rats by light microscopy
Observation of ovaries in neonatal rats by electron microscopy
Serum androgen and estrogen levels
Comparison of serum hormone levels among Group B’, C’, and D’ a
3.84 ± 0.63b
50.11 ± 7.98d
9.07 ± 1.42c
30.67 ± 6.89ef
2.59 ± 0.42
39.56 ± 3.75
In this study, we demonstrated that elevated androgen levels during pregnancy significantly disrupted pregnancy and leaded to a PCOS-like syndrome in the female offspring. No pregnancies occurred in rats receiving daily injections of androgens throughout pregnancy, even after 10 estrus cycles. Exfoliative cytoscopy of their vagina showed no typical periodic changes associated with estrus, while rats treated with androgens during the first and second halves of pregnancy were able to undergo pregnancy after an initial period of infertility. Therefore, consisting with earlier reports [19, 20, 25], our data showed that high androgen levels during pregnancy had significant negative impacts on fertilization and could lead to permanent histopathological alterations in ovaries of female offspring (Table1, Figure 1 2 3).
Our results demonstrated that the offspring survival rate of rats treated with androgens during the first halves of pregnancy was lower than that of rats treated with androgens during the second halves of pregnancy or controls (P < 0.05). Our data was consist with studies of Dumesic et al., who reported that rhesus monkeys exposed to high androgen during the first trimester showed deficient oocyte development compared to mothers treated during the third trimester . It has been found that oocytes collected from rhesus monkeys with early prenatal androgenization were normally fertilized but abnormal development occurred after 8 cell phases compared to the control group , partially due to prematurity and aging of oocytes at ovulation and corresponding high spontaneous abortion rate. The reason for this might come from hormone disruption by androgen in the early stage of embryo development. It was known that high androgen levels during the first trimester disrupted fetal gonad differentiation, pancreas formation, and neuroendocrine development. During the first half of pregnancy, androgen administration increased the secretion of Gonadotropin-releasing hormone (GnRH) in the fetuses, which might also elevate maternal GnRH through the umbilical arteriovenous circulation and disrupt the whole maternal hypothalamus-pituitary-gonadal axis. Therefore, mothers exposed to high androgen during the first trimester might suffer more adverse effects on fertility than those exposed during the second and third trimesters.
In this experiment, there were significant differences in ovary weights and morphology between controls and rats treated with androgens during the first and second halves of pregnancy. Significant morphologic differences between the androgen-treated groups and the control group were observed by light microscopy while changes in organelle structures were observed by electron microscopy (Figure 1, 2, 3). In addition, excessive theca cells caused an elevation in serum sex hormones (Table 1). Since organ morphology is always linked with its function, the PCOS resembling histopathological alterations in ovaries of prenatal androgenized female rats suggested that androgen affects the ovary development first and consequent functions later. Because the aggregation of follicles and the morphologic changes are important characteristic in PCOS develop, our observation supported that these morphologic changes might result from androgen excess.
High androgen during early pregnancy, similar to congenital adrenal hyperplasia, is characterized by increased secretion of LH, which causes secondary ovarian hyperandrogenism. It is believed that prenatal exposure to high androgen activates the expression of androgen receptor genes in the preoptic area of the fetal hypothalamus and inhibits the estrogen-induced expression of progesterone receptor genes or even causes permanent impairment in receptor expression. Thus, secretion pattern of GnRH is no longer feminine; rather, the basic GnRH pulse generator is characterized by frequent secretion but fails at a secretion higher frequency when the E2 peaks. Previous studies have observed metabolic disturbances in adult offspring. Newborn rats prenatally exposed to high androgen during the third trimester developed hyperandrogenism but no obvious metabolic syndrome as evidenced by normal body weights and the oral glucose tolerance test (OGTT). The serum androgen concentration in Group C' was significantly higher than the other groups (Table 1). In addition, organelles involved in the synthesis of proteins (rough ER and Golgi) significantly increased but their morphologic structures were impaired (Figure 3), which might be related to the imbalance in hormone synthesis.
Abnormal metabolism in women may be unrelated to hyperandrogenism following clinical development of PCOS; rather, it reflects an ovarian structural abnormality that causes dysfunction of the hypothalamus-pituitary-growth axis or pancreatic islands, leading to both abnormal metabolism and hyperandrogenism. Since functions are based on structures, and ovarian structural abnormality leads to dysfunction, further research is required to determine the details in PCOS development and to improve the symptomatic treatment for this disease.
In this study, our data supported that androgen excess severely impact female rat fertility. Using a rat model of PCOS by injecting DHEAS into pregnant females during different stages, it was found that rats injected with DHEAS throughout pregnancy completely lost fertility, and rats treated during early pregnancy exhibited more serious aberrations in fertility than rats treated during late pregnancy compared to controls. Besides elevated androgen levels during pregnancy, there were significant increases of ovary weights in offspring of rats treated with DHEAS. The female offspring of androgen-treated rats also exhibited significant morphologic differences and organelle structure changes in ovaries. These PCOS resembling histopathological alterations in ovaries of prenatal androgenized female rats suggested that androgen affects both ovary development and its function. Therefore, our study indicated excess androgen during pregnancy, especially at the early stage, may cause high reproductive toxicity and abnormal morphology and functions of ovaries in female offspring.
Fang Wang and Bolan Yu contributed equally to this work
polycystic ovary syndrome
phosphate buffered saline
follicle stimulating hormone
oral glucose tolerance test.
This study was supported from Scientific Research Grant from By Guangdong Provincial Bureau of Health to F.W. (No.A2010271) and Scientific Research Grant from the Third Affiliated Hospital of Guangzhou Medical University to B.Y. and X.X.
- Norman RJ, Dewailly D, Legro RS, Hickey TE: Polycystic ovary syndrome. Lancet 2007, 370: 685–697. 10.1016/S0140-6736(07)61345-2PubMedView ArticleGoogle Scholar
- Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89: 2745–2749. 10.1210/jc.2003-032046PubMedView ArticleGoogle Scholar
- Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998, 83: 3078–3082. 10.1210/jc.83.9.3078PubMedGoogle Scholar
- Crosignani PG, Nicolosi AE: Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod Update 2001, 7: 3–7. 10.1093/humupd/7.1.3PubMedView ArticleGoogle Scholar
- de Zegher F, Ibanez L: Early Origins of polycystic ovary syndrome: hypotheses may change without notice. J Clin Endocrinol Metab 2009, 94: 3682–3685. 10.1210/jc.2009-1608PubMedView ArticleGoogle Scholar
- Dumesic DA, Abbott DH, Padmanabhan V: Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord 2007, 8: 127–141. 10.1007/s11154-007-9046-0PubMed CentralPubMedView ArticleGoogle Scholar
- Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kemnitz JW: Insights into the development of polycystic ovary syndrome (PCOS) from studies of prenatally androgenized female rhesus monkeys. Trends Endocrinol Metab 1998, 9: 62–67. 10.1016/S1043-2760(98)00019-8PubMedView ArticleGoogle Scholar
- Zhou R, Bird IM, Dumesic DA, Abbott DH: Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90: 6630–6637. 10.1210/jc.2005-0691PubMed CentralPubMedView ArticleGoogle Scholar
- Wild RA, Umstot ES, Andersen RN, Ranney GB, Givens JR: Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism. Am J Obstet Gynecol 1983, 146: 602–606.PubMedGoogle Scholar
- Ibanez L, Dimartino-Nardi J, Potau N, Saenger P: Premature adrenarche–normal variant or forerunner of adult disease? Endocr Rev 2000, 21: 671–696. 10.1210/er.21.6.671PubMedGoogle Scholar
- McCartney CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, Yoo R, Chang RJ, Foster CM, Caprio S, Marshall JC: Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab 2007, 92: 430–436.PubMed CentralPubMedView ArticleGoogle Scholar
- Abbott DH, Barnett DK, Levine JE, Padmanabhan V, Dumesic DA, Jacoris S, Tarantal AF: Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys. Biol Reprod 2008, 79: 154–163. 10.1095/biolreprod.108.067702PubMed CentralPubMedView ArticleGoogle Scholar
- Abbott DH, Tarantal AF, Dumesic DA: Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am J Primatol 2009, 71: 776–784. 10.1002/ajp.20679PubMed CentralPubMedView ArticleGoogle Scholar
- Bruns CM, Baum ST, Colman RJ, Dumesic DA, Eisner JR, Jensen MD, Whigham LD, Abbott DH: Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome. Int J Obes (Lond) 2007, 31: 1579–1585. 10.1038/sj.ijo.0803638View ArticleGoogle Scholar
- Dumesic DA, Patankar MS, Barnett DK, Lesnick TG, Hutcherson BA, Abbott DH: Early prenatal androgenization results in diminished ovarian reserve in adult female rhesus monkeys. Hum Reprod 2009, 24: 3188–3195. 10.1093/humrep/dep324PubMed CentralPubMedView ArticleGoogle Scholar
- Manikkam M, Steckler TL, Welch KB, Inskeep EK, Padmanabhan V: Fetal programming: prenatal testosterone treatment leads to follicular persistence/luteal defects; partial restoration of ovarian function by cyclic progesterone treatment. Endocrinology 2006, 147: 1997–2007.PubMedView ArticleGoogle Scholar
- Sarma HN, Manikkam M, Herkimer C, Dell'Orco J, Welch KB, Foster DL, Padmanabhan V: Fetal programming: excess prenatal testosterone reduces postnatal luteinizing hormone, but not follicle-stimulating hormone responsiveness, to estradiol negative feedback in the female. Endocrinology 2005, 146: 4281–4291. 10.1210/en.2005-0322PubMedView ArticleGoogle Scholar
- Veiga-Lopez A, Steckler TL, Abbott DH, Welch KB, MohanKumar PS, Phillips DJ, Refsal K, Padmanabhan V: Developmental programming: impact of excess prenatal testosterone on intrauterine fetal endocrine milieu and growth in sheep. Biol Reprod 2011, 84: 87–96. 10.1095/biolreprod.110.086686PubMed CentralPubMedView ArticleGoogle Scholar
- Demissie M, Lazic M, Foecking EM, Aird F, Dunaif A, Levine JE: Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Physiol Endocrinol Metab 2008, 295: E262-E268. 10.1152/ajpendo.90208.2008PubMed CentralPubMedView ArticleGoogle Scholar
- Wu XY, Li ZL, Wu CY, Liu YM, Lin H, Wang SH, Xiao WF: Endocrine traits of polycystic ovary syndrome in prenatally androgenized female Sprague–Dawley rats. Endocr J 2010, 57: 201–209. 10.1507/endocrj.K09E-205PubMedView ArticleGoogle Scholar
- Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC: Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000, 85: 4047–4052. 10.1210/jc.85.11.4047PubMedGoogle Scholar
- Gilling-Smith C, Willis DS, Beard RW, Franks S: Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994, 79: 1158–1165. 10.1210/jc.79.4.1158PubMedGoogle Scholar
- Abbott DH, Dumesic DA, Franks S: Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol 2002, 174: 1–5. 10.1677/joe.0.1740001PubMedView ArticleGoogle Scholar
- Franks S: Do animal models of polycystic ovary syndrome help to understand its pathogenesis and management? Yes, but their limitations should be recognized. Endocrinology 2009, 150: 3983–3985. 10.1210/en.2009-0652PubMedView ArticleGoogle Scholar
- Anderson E, Lee GY, O'Brien K: Polycystic ovarian condition in the dehydroepiandrosterone -treated rat model: hyperandrogenism and the resumption of meiosis are major initial events associated with cystogenesis of antral follicles. Anat Rec 1997, 249: 44–53. 10.1002/(SICI)1097-0185(199709)249:1<44::AID-AR6>3.0.CO;2-FPubMedView ArticleGoogle Scholar
- Dumesic DA, Schramm RD, Bird IM, Peterson E, Paprocki AM, Zhou R, Abbott DH: Reduced intrafollicular androstenedione and estradiol levels in early-treated prenatally androgenized female rhesus monkeys receiving follicle-stimulating hormone therapy for in vitro fertilization. Biol Reprod 2003, 69: 1213–1219. 10.1095/biolreprod.102.015164PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.